Truist Assigns Buy Rating to Genmab (GMAB)
Key takeaways
- According to Renza, Rina-S and petosemtamab have the potential to be best- or first-in-class in ovarian cancer and HNSCC, respectively, while Epkinly’s DLBCL-2/-4 results are crucial for franchise expansion.
- Wainwright reduced the target price on Genmab A/S (NASDAQ:GMAB) from $40 to $38, leading to an adjusted upside potential in excess of 54%.
- Genmab A/S (NASDAQ:GMAB) is a biotechnology company based in Denmark that is engaged in developing antibodies and related products to cure cancer and other diseases.
Truist Assigns Buy Rating to Genmab (GMAB) Muhammad Ali Khalid Fri, June 5, 2026 at 11:36 PM GMT+7 2 min read GMAB TFC Genmab A/S (NASDAQ:GMAB) is one of the 10 best large cap stocks under $30 with highest upside potential.
On May 27, coverage of Genmab A/S (NASDAQ:GMAB) was resumed by Truist analyst Gregory Renza. The analyst reduced the price target from $48 to $40 and assigned a Buy rating to the stock. He shared an optimistic view about the company following its shift towards a commercially focused business platform. This is backed by three key assets comprising around seven important readouts during 2026.
According to Renza, Rina-S and petosemtamab have the potential to be best- or first-in-class in ovarian cancer and HNSCC, respectively, while Epkinly’s DLBCL-2/-4 results are crucial for franchise expansion.